Factor X (factor ten) of the coagulation cascade binds to the integrin CD11b/CD18 during inflammation, initiating procoagulant activity on the surface of leukocytes (Altieri, Invest. 1995Invest. . 95:1078Invest. -1085 
Introduction
The leukocyte integrin CDllb/CD18 (Mac-i, CR3) plays an important role in leukocyte trafficking during inflammation. Activated CDI lb/CD 18 promotes the firm adhesion of leukocytes to endothelial cells (1) (2) (3) . Eukaryotic ligands for CDI ib/CD18 are known to include coagulation Factor X, C3bi, and intercellular adhesion molecule-i (ICAM-i )' on endothelial cells, and fibrinogen (3) (4) (5) (6) (7) . This combination of binding specificities has been suggested to provide a point of convergence of the path- ways for leukocyte adhesion and coagulation which operate during inflammation (8) .
Monocytic/myeloid cells stimulated with ADP express activated CDI lb/CD 18 which binds Factor X with high affinity in a saturable reaction (5) . In a second step, CDI lb/CD1 8-bound Factor X is converted to the proteolytically active Factor Xa, thereby initiating the coagulation cascade on the surface of monocytes and neutrophils (9) . Binding of Factor X to CDI lb/ CD18 has been demonstrated to be mediated by three surface loops: GYDTKQED (residues 366-373), IDRSMKTRG (422-430), and LYQAKRFKV (238-246) as evidenced by the ability of peptides representing these three binding regions to block radiolabeled Factor X binding to the monocytic cell line, THP-1 (8) . These peptides also inhibit the generation of Factor Xa procoagulant activity.
Filamentous hemagglutinin (FHA) of Bordetella pertussis is a 220-kD nonfimbrial membrane protein that binds to cilia and macrophages of the human respiratory tract during whooping cough (10, II) . Of the several interactions FHA exhibits with macrophages, the ability to bind to the integrin CDllb/CD18 has received the most attention. To enter phagocytes without an oxidative burst, many prokaryotes bind to carbohydrate substituents on the integrin CDiIb/CD18 or become coated with C3bi (12) . In contrast, B. pertussis binds directly to the integrin in a protein-protein interaction mediated by FHA. This direct interaction has been demonstrated to occur with purified FHA and integrin (13) . Previously, the region of FHA suggested to participate in this direct binding was a domain containing an Arg-Gly-Asp (RGD) sequence (14) . More recently, it has been recognized that, although the RGD in FHA clearly promotes binding of FHA or bacteria to the integrin presented on cells, binding of purified FHA to purified integrin is not influenced by RGD peptides (13) . Non-RGD-mediated interactions may therefore explain the direct binding between FHA and CDiIb/CD18. While delineation of the mechanism of this interaction is of obvious importance to understanding the pathogenesis of whooping cough, it is also of potential value as a unique probe into the biology of the CDiIb/ CD18 adhesion molecule.
Here 12 ,000 g for 2 min. Aliquots of the supernatant (cell free l'2I-Factor X) and the cell pellet (cell bound "2I-Factor X) were counted in a gamma counter. Nonspecific binding (-50,000 cpm) was determined by adding a 100-fold excess of unlabeled Factor X, and subtracted from total radioactivity (-500,000 cpm for controls). (16. 17) . Specific pathogen-free, New Zealand White rabbits (2 kg; Hare Marland, Nutley, NJ) were anesthetized with Valium (2.5 mg/kg, subcutaneously; HoffmanLaRoche, Nutley, NJ), ketamine (35 mg/kg, intramuscularly; Aveco Co., Fort Dodge, IA), and xylazine (5 mg/kg, intramuscularly; Miles Laboratories, Shawnee, KS), and a helmet of dental acrylic was affixed to the calvarium. 24 h later, the rabbits were anesthetized with ethyl carbamate (1.75 g/kg; Aldrich Chemical Co., Milwaukee, WI) and pentobarbital (15 mg/kg; Abbott Laboratories, Abbott Park, IL) and placed in a stereotaxic frame. A spinal needle was introduced into the cisterna magna, and 300 MIl of cerebrospinal fluid (CSF) was withdrawn.
The animals were challenged intracistemally with 108 heat-killed, unencapsulated pneumococcus strain R6 introduced in 200 pi of saline (time 0). 1 h later animals were treated with peptides dissolved in I ml of saline by intravenous injection into the right marginal ear vein. Samples of CSF were withdrawn at hourly intervals after pneumococcal inoculation, and leukocyte density was measured using a counter (Coulter Corp., Hialeah, FL). CSF samples were centrifuged at 10,000 g for 5 min, and the supernatant was stored at -70°C until assayed for protein concentration using the bicinchoninic acid method (BCA kit; Pierce Chemical Co.) and for lactate concentration (lactate detection kit; Sigma Chemical Co.). Differences between treatments were determined by one-way ANOVA.
Determination ofstability ofpeptides in rabbit plasma. Rabbit blood was heparinized and centrifuged to yield plasma. Peptides were dissolved in PBS (120 mM NaCl, 2.7 mM KCI, 1.9 mM NaH2PO4, and 8.1 mM Na2HPO4) at a concentration of 62.5 pM. The peptides were mixed with an equal volume of plasma, and the samples were analyzed by HPLC at 0, 2, 4, 6, 8, 24, and 48 h. Analysis was performed on a Hewlett-Packard (Palo Alto, CA) 1090 HPLC using a protein and peptide column (C18; VYDAC, Hesperia, CA) (4.6 mm x 250 mm, 5-prm particle size) equilibrated with 0.1 M sodium perchlorate/0.1% phosphoric acid (85%) in water, at pH 2.5, and eluted with acetonitrile in a gradient from 0 to 40% over 40 min (flow I ml/min; monitored at 210 nm).
Results
Sequence similarity between FHA and the CD] b/CD18 binding sites of Factor X. The amino acid sequence of FHA was compared with that of the three regions of human coagulation Factor X that are known to bind to the leukocyte integrin CD1 lb/CD18 (8) . Sequence similarity (40-70% identity) was found between amino acid residues 238-246, 366-373, and 422-430 of Factor X (according to Fung et al. [18] ) and FHA residues 1979-1984, 2062-2068, 32-36, and 2523-2533 (according to Relman et al. [19] ) (Table I) .
FHA peptides block Factor X binding to leukocytes. In accordance with previous observations (8), three peptides from Factor X inhibited 125I-Factor X binding to leukocytes by 50-90% ( Fig. 1 A, stippled bars) . Native FHA and FHA peptide II showed strong inhibition of '25I-Factor X binding to neutrophils of 70±4 and 87±8%, respectively ( Fig. 1 A, shaded bars) . The other FHA peptides also demonstrated significant inhibition, but to a lesser extent than the corresponding Factor X peptides. Native FHA, FHA peptide II, and the corresponding Factor X peptide II inhibited 1251-Factor X binding in a concentration-dependent manner (Fig. 1 B) .
FHA peptides inhibit Factor Xa procoagulant activity on monocytes. Binding of Factor X to leukocytes is followed by conversion to Factor Xa and initiation of coagulation. Factor Xa generation on activated THP-1 cells in the absence of peptide or in the presence of a control peptide (a scrambled FHA II analogue) was > 110 ng/ml (Table II) . The concentration of Factor Xa correlated inversely with the clotting time. Factor X peptides I and II decreased Factor Xa production (< 40 ng/ ml), thereby significantly prolonging clotting time (Table II) . FHA peptides Ia, Ib, and III also significantly reduced Factor Xa production by 50-70%. Although FHA peptide II reduced the generation of Factor Xa procoagulant activity by only 25%, the NH2-terminal acetylated and COOH-terminal amidated form of this peptide significantly enhanced this effect.
FHA peptides inhibit adherence and transendothelial mi- Fig. 2 B, native FHA, Factor X-, and FHA-peptides were found to inhibit neutrophil adherence in a concentrationdependent manner. Since CDl 8-dependent leukocyte adherence to activated endothelia is a prerequisite to transendothelial migration, the FHA and Factor X peptides were tested for the ability to prevent neutrophil transmigration in vitro (Table I) . mAb IB4 (25 ,ug/ ml) reduced transendothelial migration by 73±14% (not shown). In concordance with the results in the adherence assay, FHA peptides Ia and II showed consistently detectable activity, although the magnitude of the effect was low ( 20%). (Table  I ). This activity was greatly augmented by the acetyl/amide modification of FHA II, leading to an inhibition of 61t+6%.
From this and the neutrophil adherence analyses, FHA peptides Ia and II were identified as candidates for more extensive testing.
Several experiments were done to investigate the mechanism by which these peptides inhibited adherence and transendothelial migration of neutrophils. First, we sought to determine whether they could enhance the ability of mAb IB4, a strong inhibitor of neutrophil transendothelial migration, to block neutrophil adherence to endothelial cells. [log p.MJ Figure 2 . Inhibition of neutrophil adherence to activated endothelial cells by FHA, Factor X-, and FHA-derived peptides. Fluoresceinated human neutrophils were incubated with peptides (designated as in Table  I ) and then allowed to adhere to activated HUVEC monolayers. After washing, the number of adherent neutrophils was counted in a 40x microscope field and expressed as a percentage of adherence in control wells with neutrophils treated with buffer alone. A, peptides 500 pM, native FHA 0.1 pM; values represent the mean±standard deviation of Table I ). Taken together, these results indicate that the peptides are acting at a site independent of that bound by IB4. We also investigated the possibility that the proteolytic activity associated with the X to Xa conversion might promote leukocyte transmigration. This hypothesis would predict a correlation between inhibition of the generation of Factor Xa (i.e., an anticoagulant effect) and inhibition of leukocyte transmigration. The discordance of the anticoagulant effects of FHA peptides Ta, Tb, and III and the poor antimigration effects (compare Tables I and II) argues against this hypothesis. Similarly, the protease inhibitor leupeptin inhibited generation of Factor Xa (> 90% inhibition, Table II ) but failed to block leukocyte transmigration (6±6% inhibition as performed according to Table I at 25 itg/ml). This result suggests that proteolytic activity is not correlated with transmigration and that the peptides are unlikely to exert their effect on neutrophil migration by inhibiting proteolysis associated with coagulation factors.
The antiinflammatory effect of FHA peptides with Factor X homology in vivo. To determine if the ability to block neutrophil attachment and transmigration in vitro predicted antiinflammatory activity in vivo, several peptides were tested in an animal model of pneumococcal meningitis for the capacity to prevent leukocyte extravasation from the bloodstream into the CSF. Native FHA and FHA-and Factor X-derived peptides were injected intravenously 1 h after intracistemal challenge with pneumococci. Fig. 3 depicts the leukocyte response over 7 h. Native FHA, FHA peptides I and II, and Factor X peptide II resulted in a significant reduction of CSF leukocytosis of > 60% (P < 0.05). The scrambled FHA peptide II was ineffective (P > 0.5).
To determine the stability of the FHA II peptide, the unmod- ified or the acetylated-amidated peptide was incubated in 50% rabbit plasma at 37°C. The concentration of unprotected FHA peptide II was decreased by half in 4-6 h, whereas the concentration of the acetylated-amidated derivative remained un- changed over 48 h. Rabbits (n = 10) were treated with 10 nmol of the acetyl-amide-FHA II. Control animals (n = 10) exhibited a mean of 6,480+684 leukocytes/,ul CSF at 6 h after pneumococcal challenge. In contrast, animals receiving the acetylamide-FHA II demonstrated a significant reduction of leukocyte migration into the CSF to 3,011+684 cells/,ul (P = 0.0015, ANOVA) (Fig. 4) . Protection against blood brain barrier permeability afforded by FHA peptides. Loss of barrier function of the cerebral capillary endothelium during inflammation is reflected by an influx of serum proteins into the CSF, and impaired cerebral metabolism has been shown to correlate with increased lactate concentrations in CSF (17) . An effective antiinflammatory agent should ameliorate both of these parameters of injury. To examine if the ability of the peptides to decrease leukocyte transmigration correlated with improvements of these measures of cerebral injury, CSF protein and lactate concentrations were measured in peptide-treated and control animals (Table IV) . FHA peptide II and its acetyl-amide derivative significantly reduced protein influx into the CSF and generation of lactate (P < 0.02). FHA peptide I and Factor X peptide II did not cause a significant reduction in protein influx, a finding indicating a greater potency of FHA peptide II.
Discussion
The binding of Factor X to the integrin CD1lb/CD 18 on the surface of ADP-activated monocytic cells initiates cleavage of the zymogen Factor X to Factor Xa and thereby activates the coagulation cascade in the microenvironment of an inflamed tissue (9) . The binding sites on Factor X have been mapped to three spatially separate regions which contact the alpha subunit Fig. 3 . 10 control animals received PBS. Values represent mean±standard deviation of concentrations in CSF at 6 h after pneumococcal challenge (n 2 4 for peptide-treated animals; n = 4 for FHA). * Statistically significant difference as compared with control at P < 0.02.
of the integrin CDl1b/CD18 (8) . The present study provides evidence that the binding of a prokaryotic adhesive protein, FHA, to CD1lb/CD18 mimics at least one binding loop of Factor X. FHA binds to cell-associated and purified CDllb/ CD18 (13, 14) . Binding of FHA strongly inhibits subsequent binding of radiolabeled Factor X to the activated integrin. This property appears to reside, at least in part, in the sequence ETKEVDG since this FHA peptide inhibited '25I-Factor X binding to stimulated neutrophils by > 80%, while three other regions of FHA were less effective. This peptide resembles DTKQED, the Factor X peptide which defines one binding loop for CD1 lb/CD 1 8. The differences in the sequences ETKEVDG and DTKQED suggest that alteration of three residues in the Factor X peptide sequence does not influence the activities measured: aspartic acid to glutamic acid, glutamine to glutamic acid, and glutamic acid to valine. The fact that both FHA and Factor X peptides displayed activity suggests the importance of the conserved threonine, lysine, and aspartic acid or the spatial array of three acidic and one basic amino acid side chains. The inhibition of binding of 125I Factor X to leukocytes by the Factor X-derived peptide DTKQEDG was associated with a strong anticoagulant effect as measured by clotting time and generation of Factor Xa. The FHA peptide ETKEVDG showed a modest anticoagulant effect which was enhanced by acetyl/ amide modification of the peptide. Significant inhibition of coagulation was also characteristic of two other FHA peptides. Thus, three regions of FHA present sequence and functional similarity to binding loops of Factor X. To our knowledge, this is the first example of a bacterial peptide modulating the triggering of the coagulation cascade on the leukocyte surface.
It is of interest to note that another pathogen, Herpes simplex virus, encodes a Factor X receptor which recognizes the same three surface loops of Factor X as does CD1lb/CD18 (8) . It now appears that the converse situation also exists, i.e., a bacterium B. pertussis, displays Factor X homology regions that bind to native CDllb/CD 18 by sequences similar to native Factor X. Given the importance of the CD1 lb/CD18-dependent entry o~~~0 0~~0~~õ -w 0 0~~0 0 0 a of this pathogen into macrophages, this mimicry may provide an important mechanism to promote intracellular localization of the bacteria and thereby prolong the course of whooping cough. A predictable consequence of this binding is the inhibition of procoagulant activity. However, an additional effect of the FHA peptides, especially ETKEVDG, is to interfere with the ability of CD1 lb/CD18 to mediate binding and transmigration of leukocytes across endothelia. This unexpected effect and its relationship to activities of Factor X were dissected in more detail.
CDllb/CDI8 promotes the firm adherence of neutrophils and monocytes to inflamed endothelia (1, 3, 6 ). The effect of the binding of Factor X to the integrin on its ability to participate in neutrophil transmigration has not been reported previously. We examined whether the Factor X-peptides and FHA-peptides could block adherence and transendothelial migration of leukocytes. Native FHA and FHA peptides LGYQAK and ET-KEVDG inhibited neutrophil adherence to activated cultured endothelial cells.
LGYQAK was clearly more effective than the corresponding Factor X peptide, GLYQAK (42 vs 18%, respectively); Factor X-derived DTKQEDG was similar in inhibitory activity to FHA-derived ETKEVDG (38 vs 32%, respectively). When peptides were tested for their ability to prevent migration of neutrophils across monolayers of activated endothelial cells, again LGYQAK and ETKEVDG were the most effective peptides (23 ±5 and 21 + 10% inhibition, respectively) and showed greater inhibition than the related Factor X peptides (10±6 and 14±9% inhibition). Activity of the ET-KEVDG peptide was strikingly increased from 21 to 61% by introducing acetyl/amide modifications. This effect may arise from greater stability of the modified peptide (static plasma half-life prolonged from 4 to > 48 h) (20) , improved presentation of the relevant sequence to the integrin receptor, or sequestration of charge effects.
Several possible mechanisms underlying the effect of Factor X-like peptides on CD18-mediated adherence of leukocytes were examined. The proteolytic activity of Factor Xa is unlikely to be involved since leupeptin did not affect leukocyte migration. In addition, strongly anticoagulant peptides (e.g., GLY-QAKRFKVG) failed to block neutrophil adherence and migration. However, a formal elimination of this hypothesis will require development of Factor X with mutations ablating proteolytic action but not binding to cells.
Inhibition of leukocyte adherence to endothelium could also arise if the region of CDllb/CD18 which binds endothelium was identical with or located near the Factor X binding site. This does not appear to be the case since Altieri has evidence that Factor X does not bind to the ICAM-l binding domain of CD1 lb (Altieri, D. C., personal communication). Our observations also appear to be independent of ICAM-1 in that the peptides did not alter the inhibition of leukocyte adherence by IB4 which interferes with CDllb/CD18 binding to ICAM-1; rather, they were additive with IB4. Thus, it appears that Factor X influences adherence between leukocyte and endothelium by an interaction that is distinct from CDllb/CD18 binding to ICAM-1. These experiments do not distinguish if Factor X or its derivative, Factor Xa, acts directly or indirectly on such an adhesion process.
The CD1 lb/CD18 adhesion molecule is an important target of strategies to develop antiinflammatory agents of therapeutic value. In the animal model of pneumococcal meningitis used here, leukocyte migration is strongly CD18 dependent (21) . Intravenous injection of native FHA, the FHA peptides LGY-QAK, ETKEVDG, acetyl/amide ETKEVDG, or the corresponding Factor X peptide GYDTKQEDG resulted in a > 70% reduction of leukocyte recruitment into the CSF at 7 h after intracisternal challenge with pneumococci. This effect is comparable with that achieved in this system by treatment with steroids (21) (22) (23) . To be of therapeutic significance, antiinflammatory agents must also prevent compromise of the barrier function of the cerebral capillary endothelium. ETKEVDG and its acetyl-amide derivative, the peptides most effective at inhibiting leukocyte migration, also effectively reduced influx of serum proteins into the CSF and accumulation of CSF lactate.
Currently, antiinflammatory therapy is recommended as an adjunct to antibiotics to decrease the morbidity and mortality of meningitis (22, 23) . One such therapeutic candidate is an anti-CD18 antibody (21) . The data presented here indicate for the first time that peptides are also viable therapeutic alternatives. Peptides have theoretical advantages in that they are more easily produced and are more amenable to multiple dose therapy as they are less antigenic. The precise mechanism of the in vitro and in vivo action of the peptides described here remains to be determined. However, the potential to deploy peptides which block both leukocyte transmigration as well as the coagulation cascade at sites of inflammation may afford added therapeutic advantage. The use of peptides patterned after regions of Factor X to reduce leukocyte accumulation in the CSF represents a novel antiinflammatory strategy.
